Supriya Lifescience Ltd
Supriya Lifescience Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Supriya Lifescience targets approximately 20% annual revenue growth for FY27 and beyond. Supriya Lifescience targets approximately 20% annual revenue growth for FY27, supported by new product launches and scaling existing products.
From Supriya Lifescience Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Supriya Lifescience targets approximately 20% annual revenue growth for FY27 and beyond.
- Expectation to achieve INR1,000 crores revenue milestone in FY27 supported by:
- Scale-up of existing product basket in regulated markets.
- Launch of 3 to 4 new products per year, with new products contributing around 10% of revenue in 2-3 years.
- Commercial revenue from the newly commissioned Ambernath finished formulation facility starting Q4 FY26, with full impact in FY27.
- Backward integration is increasing, currently at 74%, expected to rise to 80-82% soon.
- Long-term aim includes healthy growth via new products, contract manufacturing, and CDMO pipeline.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Supriya Lifescience Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex for 9MFY26 was INR 71 crores, mainly for the Ambernath facility.
- Remaining FY26 capex expected around INR 15 crores for maintenance and small projects like Riboflavin block and formulation plant needs.
- Planned ground-breaking for Patalganga site utilities block in coming year with initial INR 40-50 crores investment.
- Future plan includes setting up either an API or formulation facility at Patalganga targeted around FY29.
- Ambernath facility capex estimated between INR 140-160 crores; commercial revenue expected from Q4 FY26, EBITDA positive around Q3 FY27.
2 more points management made on capital expenditure plans
Fundraising & Capital Structure
See what Supriya Lifescience Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has good visibility on the order book for Q4 FY26, confident of achieving the revenue targets.
- Supriya Lifescience is not quantifying the exact order book but confirms firm visibility and volume commitments from customers.
- For the ATS-8 product for FY27, they have identified annual consumption for end users, with many in the signing stage of volume commitments.
- Large contracts for CDMO/CMO are under discussion, with term sheets being signed; announcements expected in coming quarters.
2 more points management made on order book & pipeline
Supriya Lifescience Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹277 Cr, net profit ₹74 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Supriya Lifesci.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences Ltd (Q3 FY26)
180.0 crore, up from Rs. Key concall takeaways from RPG Life Sciences Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] . Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Morepen Laboratories Ltd (Q3 FY26)
488 crores, up 17% from Q3 FY25 Rs. Key concall takeaways from Morepen Laboratories Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q3 FY26)
2,143 Cr., up from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Supriya Lifescience Ltd Q3 FY26 results?
Supriya Lifescience targets approximately 20% annual revenue growth for FY27 and beyond. Supriya Lifescience targets approximately 20% annual revenue growth for FY27, supported by new product launches and scaling existing products.
What is Supriya Lifescience Ltd share price analysis?
Supriya Lifescience Ltd currently shows a neutral. The stock trades at a P/E of 35.1 with a market cap of ₹7,353 Cr. Investors should review the full earnings analysis for detailed insights.
Is Supriya Lifescience Ltd planning capital expenditure?
Capex for 9MFY26 was INR 71 crores, mainly for the Ambernath facility.
Keep Supriya Lifescience Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.